MONOAMINE-OXIDASE INHIBITORS, COGNITIVE FUNCTIONS AND NEURODEGENERATIVE DISEASES

被引：0
作者：
DELUMEAU, JC
BENTUEFERRER, D
GANDON, JM
AMREIN, R
BELLIARD, S
ALLAIN, H
机构：
[1] UNIV HOSP RENNES,EXPTL & CLIN PHARMACOL LAB,F-35033 RENNES,FRANCE
[2] TECHNOPOLE RENNES ATALANTE,BIOTRIAL,RENNES,FRANCE
[3] F HOFFMANN LA ROCHE & CO LTD,CNS,PHARMA CLIN RES,CH-4002 BASEL,SWITZERLAND
来源：
JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT | 1994年 / 41期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Recent data obtained in animals and in humans suggest that both MAO-A and MAO-B inhibitors present cognitive enhancing properties of possible interest in the treatment of cognitive disorders. In addition, the rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. It seems then worthwile to investigate the neuroprotective effect of MAOIs in humans and to assess, furthermore, the real therapeutical benefit of their cognitive enhancing properties.
引用
收藏
页码：259 / 266
页数：8
相关论文
共 39 条
[1]  
ALLAIN H, 1992, PSYCHOPHARMACOLOGY S, V106, P56
[2]   THE PHARMACOLOGY OF REVERSIBLE MONOAMINE-OXIDASE INHIBITORS [J].
AMREIN, R ;
ALLEN, SR ;
GUENTERT, TW ;
HARTMANN, D ;
LORSCHEID, T ;
SCHOERLIN, MP ;
VRANESIC, D .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 155 :66-71
[3]  
Anand R, 1990, Adv Neurol, V51, P261
[4]  
BAUMHACKL U, 1991, AUG C INT PSYCH ASS
[5]   INCREASED LIFE EXPECTANCY RESULTING FROM ADDITION OF L-DEPRENYL TO MADOPAR TREATMENT IN PARKINSONS-DISEASE - A LONGTERM STUDY [J].
BIRKMAYER, W ;
KNOLL, J ;
RIEDERER, P ;
YOUDIM, MBH ;
HARS, V ;
MARTON, J .
JOURNAL OF NEURAL TRANSMISSION, 1985, 64 (02) :113-127
[6]  
BYRNE E, 1992, CURR OPIN RHEUMATOL, V4, P754
[7]  
CAMPI N, 1990, CLIN THER, V12, P306
[8]  
DAPRADA M, 1990, J NEUR TR S, V29, P279
[9]  
DAPRADA M, 1989, J PHARMACOL EXP THER, V248, P400
[10]  
DAPRADA M, 1990, ACTA PSYCHIATR SCA S, V380, P7
1234